 Click on audio icon to view synchronised audio and slide presentation. Full text transcript will be posted mid-January, 2000. |
 |
| Session I |
|||
| Chair: Dr David Cavalla (Arachnova) |  |
||
|
|||
|
|
||
|
|||
|
|||
| Pharmaceutical R&D in the third millennium Dr James Niedel (Glaxo Wellcome) |
|
 |
|
|
|||
 |
|||
|
|||
 |
|||
|
|||
| Development of RemicadeTM (infliximab) for chronic
inflammatory diseases: lessons learned from the Crohn’s disease and rheumatoid
arthritis experience Dr Tom Schaible (Centocor) |
|
|
|
|
|||
|
|||
|
|||
|
|||
|
|||
| Relenza: a rationally designed anti-influenza drug Dr Rob Fenton (Glaxo Wellcome) |
|
|
|
|
|||
|
|||
|
|||
|
|
||
|
|||
| Session II |
|||
| Chair: Dr Irene François (SMR Chairman) | |
||
|
|||
|
|||
| Zyprexa (olanzapine): an atypical antipsychotic agent Dr David Tupper (Lilly, UK) |
|
||
|
|||
|
|||
|
|||
|
|||
| Alosetron – the discovery of a novel treatment for
irritable bowel syndrome Prof Pat Humphrey OBE DSc (Glaxo Wellcome) |
|
|
|
|
|||
|
|||
|
|||
|
|
||
|
|||
| Session III |
|||
| Chair: Dr Simon Hodgson (Glaxo Wellcome) | |
||
|
|||
|
|||
| Leflunomide - the development story Dr Uli Elben (Aventis) |
|
|
|
|
|||
|
|||
|
|||
|
|||
| Celecoxib (SC58635): Discovery and development of COX-2
specific inhibitors Dr Tim Maziasz (Searle, USA) |
|
|
|
|
|||
|
|||
|
|||
|
|||
|
|||
| [ Welcome ] [ Webcast ] [ Faculty ] [ About SMR ] [ Technical Instructions ] | |||
|
|||
 |
|||
|
|||
| Webcast produced by Prous Science |
|||
|
© 2000 Prous Science. All rights reserved Send comments and questions to service@prous.com Legal Notice |
|||
|
|||